The Limited Times

Now you can see non-English news...

Covid-19: Pfizer / BioNTech announces “100%” effectiveness of its vaccine in 12-15 year olds

2021-03-31T12:34:37.646Z


The two laboratories hope to start administering it to this age group for the next school year. The Pfizer / BioNTech Covid-19 vaccine is 100% effective in adolescents aged 12 to 15. This is what emerges from the analysis of the results of a clinical trial, announced this Wednesday the two laboratories which hope that the vaccination of this age group will begin before the next school year. Phase 3 trials involving 2,260 adolescents in the United States "have demonstrated 100% efficacy and


The Pfizer / BioNTech Covid-19 vaccine is 100% effective in adolescents aged 12 to 15.

This is what emerges from the analysis of the results of a clinical trial, announced this Wednesday the two laboratories which hope that the vaccination of this age group will begin before the next school year.

Phase 3 trials involving 2,260 adolescents in the United States "have demonstrated 100% efficacy and robust antibody responses," the companies said in a statement.

Pfizer and BioNTech will now submit this data to various regulatory authorities around the world "in the hope of starting to vaccinate this age group before the start of the next school year", says Albert Bourla, CEO of the American pharmaceutical giant .

25% more doses for 2021

The CEO of the German laboratory BioNTech, Ugur Sahin, believes that the results for 12-15 year olds are "very encouraging given the trends observed in recent weeks concerning the spread" of the British variant of the virus.

Children are less exposed to severe cases of the disease, while transmitting it less for the youngest of them (under 10 years).

Their vaccination has therefore not been a priority for the moment.

READ ALSO>

Covid-29: the events of the day live

The Pfizer / BioNTech vaccine, based on innovative messenger RNA technology, was the first vaccine against Covid-19 approved in the West at the end of 2020. The United States and the European Union have both authorized its use for people aged 16 and over.

It has since been used in millions of adults in over 65 countries.

A real-life study of 1.2 million people in Israel has shown that it is 94% effective against asymptomatic forms, 97% effective against severe and symptomatic forms.

Last week, BioNTech and Pfizer launched clinical studies in children, on a first group aged 5 to 11 years.

A younger cohort of children aged 2 to 5 is expected to receive their first dose next week as part of the study which will also cover children aged 6 months to 2 years.

BioNTech said on Tuesday it expects to manufacture 2.5 billion doses of its vaccine this year, 25% more than initially forecast.

Source: leparis

All life articles on 2021-03-31

You may like

Trends 24h

Life/Entertain 2024-03-28T17:17:20.523Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.